

Out-of-pocket prescription medicine expenditure amongst community-dwelling adults: findings from The Irish Longitudinal Study on Ageing (TILDA) in 2016

Authors: James Larkin^{1,2}, Ciaran Prendergast¹, Logan T. Murry¹, Michelle Flood¹, Barbara Clyne³, Sara Burke⁴, Conor Keegan⁵, Fiona Boland⁶, Tom Fahey², Nav Persaud^{7,8}, Rose Anne Kenny⁹, Frank Moriarty^{1,9*}

[*FrankMoriarty@rcsi.com](mailto:FrankMoriarty@rcsi.com)

1. School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
2. Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
3. Department of Epidemiology and Public Health, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
4. Centre for Health Policy and Management, School of Medicine, Trinity College Dublin, Dublin, Ireland.
5. Economic and Social Research Institute, Dublin, Ireland
6. Data Science Centre, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
7. Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
8. MAP Centre for Urban Health Solutions, St Michael's Hospital, Toronto, Ontario, Canada
9. The Irish Longitudinal Study on Ageing, Trinity College Dublin, Dublin, Ireland

Abstract

Background

The number of prescription medicines prescribed to older adults is increasing in Ireland and other countries. This is leading to higher out-of-pocket prescription medicine expenditure for older adults, which has several negative consequences including cost-related non-adherence. This study aimed to characterise out-of-pocket prescription medicine payments, and examine their relationship with entitlements, multimorbidity and adherence.

Methods

This cross-sectional study used 2016 data from a nationally-representative sample of adults in Ireland aged ≥ 50 years. Descriptive statistics and regression models were used to describe out-of-pocket prescription medicine payments and assess the association between out-of-pocket prescription medicine payments and the following variables: healthcare entitlements, multimorbidity, and cost-related non-adherence.

Results

There were 5,668 eligible participants. Median annual out-of-pocket prescription medicine expenditure was €144 (IQR: €0-€312). A generalised linear model showed that, amongst those with out-of-pocket prescription medicine expenditure, having fewer healthcare entitlements was associated with 4.74 (95% CI: 4.37-5.15) times higher out-of-pocket prescription medicine expenditure. Overall, 1.7% (n=89) of participants reported cost-related non-adherence in the previous year. A multivariable model found no significant associations between any variables and cost-related non-adherence.

Conclusions

Those with entitlements to subsidised prescription medicines had much lower out-of-pocket prescription medicine expenditure. This highlights the benefits of expanding healthcare entitlements and ensuring uptake of entitlements by those with eligibility.

1. Background

In most OECD countries, including Ireland, per capita pharmaceutical expenditure increased between 2010 and 2020,¹ with these trends expected to continue.² The primary drivers of increased per capita pharmaceutical expenditure are the development of expensive drugs³ and the increased use of prescription medicines.⁴ In Ireland, prescription medicine use has greatly increased in recent decades. For example, the concurrent use of ≥ 5 medications increased amongst those aged ≥ 65 years from an estimated 18% of the population to 60% between 1997 and 2012.⁵ These rates have further increased in recent years in Ireland⁶ and in other countries.⁷ Likely reasons include populations ageing⁸ and the increasing prevalence of multimorbidity (≥ 2 e chronic conditions in an individual).⁹⁻¹¹ Despite this, multimorbidity is an often-overlooked complicating factor in medication regimens¹² and in eligibility to publicly-funded schemes.^{13,14}

These complexities can contribute to varied approaches to how health systems provide and finance medicines for their population, which can include public financing, health insurance and user fees.¹⁵ Medications are among the most expensive components of healthcare when considering out-of-pocket payments.¹⁶⁻¹⁸ In Ireland, which has a mixed public-private healthcare system (Table 1), medicines have consistently accounted for the highest share of out-of-pocket healthcare spending for the poorest quintiles.¹⁹ Between 2009 and 2016 there was a large increase in out-of-pocket healthcare payments in Ireland, a significant proportion of this increase attributed to prescription medicines.²⁰

High out-of-pocket payments can have a range of consequences. A review of the Irish health system concluded that the burden of out-of-pocket payments for healthcare was *catastrophic* (total annual out-of-pocket health payments exceeding 40% of a household's non-subsistence income) for 1.2% of households, while a further 1% were pushed into poverty by out-of-pocket healthcare payments.¹⁹ Out-of-pocket payments can also cause cost-related non-adherence/attendance, i.e. not accessing or using recommended healthcare services/interventions due to cost, which can ultimately increase healthcare costs due to negative health outcomes.²¹ A review of studies in eleven high-income countries found that prevalence of cost-related non-adherence to prescribed medicines ranged from 1.6-16.8%, with a higher prevalence among lower income populations and lower prevalence amongst older adults.²² A study examining the introduction of small prescription medicine co-payments in Ireland found that they reduced adherence by between 2-10% depending on the medication.²³

1.1 Healthcare Coverage in Ireland

Healthcare entitlements in Ireland are 'extremely complex'.¹⁹ Prescription medicines are mainly funded through public healthcare entitlements and out-of-pocket payments.¹⁹ In 2016, 36% of the population had General Medical Services (GMS) scheme entitlements and these

were primarily low-income groups.²⁴ The GMS scheme provides for access to prescription medicines for a low co-payment (full details in Table 1 and eBox 1). Those without GMS entitlements are eligible for the Drugs Payment Scheme (DPS), which, in 2016, meant a monthly prescription medicine payment cap of €144 per household. Details of other relevant schemes are in Table 1 and eBox 1.

Table 1. Details of prescription medicine entitlement schemes

	DPS²⁵	GMS Scheme²⁶	HTD Scheme²⁷	HAA²⁸	LTI Scheme²⁹
Applicable medicines	All	All	'High Tech' Drugs	All	medicines to treat one of 16 specified health conditions
Eligibility	Those without GMS entitlements	Means tested based on income, age and household structure	Prescribed 'High Tech' Drugs by a hospital consultant	Those affected by contaminated blood products provided by the State	Individuals with any one of 16 specified health conditions
Monthly limit	€144 per household per month	€25 per household per month	€144 for DPS, €0 for all other groups	€0	€0 for applicable medicines
Co-payment limit	N.A.	€2.50 per medicine dispensed	N.A.	€0	€0 for applicable medicines

DPS=Drug Payments Scheme GMS= General Medical Services HTD=High Tech Drugs HAA=Health Amendment Act

LTI=Long Term Illness

1.2 Aim

Affordability and multimorbidity are large drivers of patients choosing to reduce, delay, or cease their prescribed medication regimen.^{30,31} However, to our knowledge a detailed analysis of out-of-pocket medicine expenditure and the divergent causes of cost-related non-adherence have not been modelled in the context of Ireland's complex healthcare entitlements system. This study aimed to characterise out-of-pocket payments for prescription medicines, and examine their relationship with entitlements, multimorbidity and adherence.

2. Methods

2.1 Study design and participants

This is a cross-sectional study, reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.³² It uses data from wave 4 of The Irish Longitudinal Study on Ageing (TILDA),³³ a nationally-representative cohort study of adults in Ireland aged ≥ 50 years. Wave 4 data collection took place in 2016 using computer aided personal interviewing (CAPI). CAPI documentation is available on the TILDA website.³⁴

2.2 Participants

Participants recruited at baseline were aged ≥ 50 years, as well as their spouses or partners of any age. Households were sampled based on a random selection process using a national geodirectory of residential addresses. Participants in residential care settings were excluded from analysis due to the likely difference between their healthcare utilisation patterns and the patterns of community-dwelling adults. Participants were also excluded if they had not answered the question on out-of-pocket prescription medicine spending or stated they do not know their expenditure, or if there had a significant cognitive impairment and were therefore not asked this question.

2.3 Variables and data sources

2.3.1 Outcomes

The primary outcome variable, out-of-pocket prescription medicine expenditure was ascertained during the CAPI where participants were asked “*Not counting health insurance refunds, on average about how much do you pay out-of-pocket for your prescribed drugs per month?*” This amount was multiplied by 12 to estimate annual expenditure. Full details of medicines questions are in Appendix A, eBox 2. With regard to outliers, data (N=13) was removed if a participant’s monthly prescription medicine expenditure was above €288 (twice the Drugs Payment Scheme limit of €144), unless there was other information provided by the participant to suggest it was plausible or an error had been made (e.g. a decimal point error in recording verbally-reported expenditure). Example cases are provided in Appendix A, eBox 3.

Participants were also asked about cost-related non-adherence: “*In the last 12 months, have you ever received a prescription from your GP that you didn’t fill with the pharmacy because you thought that the medication was too expensive?*” The response options were yes, no or don’t know/refused.

2.3.2 Exposure

The two primary exposures were healthcare entitlements and multimorbidity. Healthcare entitlements were ascertained by asking about the GMS scheme, the GP visit card, the Health Amendment Act, the LTI scheme and private health insurance (questions details in

Appendix A, eBox 4). Details of entitlements are in Table 1 and eBox 1. For analysis, those covered under the Health Amendment Act were grouped with the GMS scheme. Entitlement was categorised as GMS scheme, GP visit card, or neither of these (as mutually exclusive groups), and additionally, presence of LTI scheme entitlement and/or private health insurance. *GP Visit Cards* entitle holders to free access to general practitioners (GPs) but provides no specific medication cover.³⁵ There is limited clarity on medication subsidies provided by private health insurance^{36,37} though they are likely to be limited as most insurance plans are hospital plans.³⁸

The number and type of health conditions was ascertained by asking participants to report doctor-diagnosed conditions (Appendix A, eBox 5). The condition list for analysis was developed by combining some of the 36 conditions asked about to give 21 broader conditions (Appendix A, eBox 6) in line with previous TILDA research.³⁹ For regression analyses, the number of chronic conditions was included as a single count variable. For descriptive analysis, number of chronic conditions was analysed as a count variable and was also grouped into categories (0, 1, 2, 3+ conditions). A binary variable for presence of complex multimorbidity was also included. Complex multimorbidity was defined as the presence of at least three chronic conditions in an individual with a minimum of three conditions each primarily affecting one distinct body system (defined by the World Health Organization's International Classification of Primary Care-2, see Appendix A, eBox 7).⁴⁰

2.2.3 Covariates

Participants also reported 'regular' medications that they take 'every day or every week'. These responses were summarised to derive the number of regular prescribed medications likely to incur expenditure.

There were several demographic questions including sex, age, urban/rural residence and marital status. Participants also provided details of overall household income. Equivalised household income was used for descriptive analysis, which is an adjusted measure based on the OECD-modified equivalence scale for household size:⁴¹ household income is divided by number of people in the household, where a weight of 1 is applied to the first adult, 0.5 for each additional adult and 0.3 for each child. Level of educational attainment was also used as a proxy for socioeconomic status. For the residence variable this was operationalised using two categories: urban and not urban.

Total out-of-pocket health expenditure was determined as an individual's total reported expenditure on prescribed medications, GP visits, emergency department care, specialist medical consultations, and hospital outpatients and inpatient care reported over 12 months preceding their interview (question details in Appendix A, eBoxes 2 and 8).

2.4 Statistical analysis

Firstly, descriptive statistics were generated to describe variables of interest. This included a breakdown for each exposure variable within each age-bracket, sex, education level, area of residence (urban/non-urban), marital status, and number of regular medications (grouped in quintiles). Mean and median out-of-pocket prescription medicine expenditure are also provided for the above variables and each exposure variable.

Descriptive statistics were also generated for any out-of-pocket prescription medicine expenditure, out-of-pocket prescription medicine expenditure as a proportion of all out-of-pocket health expenditure, and financial burden of prescription medicines. Financial burden of prescription medicines is the percentage of equivalised household income spent on prescription medicines (winsorised at 100%); previously it has been applied to out-of-pocket healthcare expenditure overall.^{17,18} Equivalent descriptive statistics were generated for participants reporting cost-related non-adherence in the previous 12 months.

A two-part regression model was used to analyse the independent association of each category of healthcare entitlement and number of chronic conditions with out-of-pocket prescription medicine expenditure. The first part was a logit regression to model the binary measure of whether a person had any out-of-pocket prescription medicine expenditure or not. The second part was a generalised linear model (GLM) with log-link and gamma distributed errors which models out-of-pocket prescription medicine expenditure amongst those with any out-of-pocket prescription medicine expenditure. This two-part model allows for the presence of a large number of cases with the value zero, which often occurs for expenditure data.⁴² The two models adjusted for covariates including sex, age, education level, number of prescribed medicines, urban residence and marital status. A sensitivity analysis of the two models was conducted with number of chronic conditions included as a categorical variable.

A logit regression was conducted modelling the binary outcome of cost-related non-adherence. The primary independent variable was out-of-pocket prescription medicine expenditure, parameterised as any expenditure, and amount of expenditure. The model controlled for non-medication out-of-pocket healthcare expenditure (parameterised as any expenditure and the amount of expenditure), healthcare entitlements, demographics, and number of prescribed medications. Complete-case analysis was used for all regression models. An exploratory analysis was conducted which involved univariate logit models with the same independent variables and cost-related non-adherence as the dependent variable.

3. Results

There were 5,668 eligible participants, after exclusion of participants in residential care settings (n=78) and those who did not provide details of out-of-pocket prescription medicine expenditure (n=153). The mean age of participants was 68.1 years (SD=8.9), 55.6% (n=3,153) were female and 46.5% (n=2,632) had GMS entitlements. Overall, 30.6% (n=1,734) were taking ≥ 4 regular medications and the mean number of chronic conditions was 2.1 (SD=1.6).

Median annual out-of-pocket prescription medicine expenditure was €144 (IQR: €0- €312). Median annual out-of-pocket prescription medicine expenditure for those with GMS entitlement was €120 (IQR: €60-€240) compared to €480 (IQR: €180-€1200) for those with a GP visit card and €168 (IQR: €0-€600) for those with eligibility for neither scheme. With regard to multimorbidity, median annual out-of-pocket prescription medicine expenditure ranged from €0 (IQR: €0-€72) for those with no conditions to €240 (IQR: €120-€456) for those with three or more chronic conditions, and this pattern persisted across healthcare entitlement categories (Figure 1). Median annual out-of-pocket prescription medicine expenditure for those on six or more regular medicines was €300 (IQR: €204-€720). Full demographic and out-of-pocket prescription medicine expenditure details are in Table 2. Prevalence of individual chronic conditions and summaries of out-of-pocket prescription medicine expenditure is in Appendix A, eTable 1.

Table 2. Demographic and entitlement characteristics of sample broken down by out-of-pocket (OOP) prescription medicine expenditure

	Total % (n)	Mean OOP Prescription Medicine Expenditure (SD)	Median OOP Prescription Medicine Expenditure (IQR)
Age (years)			
<60	19.0 (1,075)	€254 (€439)	€60 (€0-300)
60-69	40.9 (2,318)	€330 (€486)	€139.2 (€0-360)
70-79	27.8 (1,574)	€325 (€464)	€153 (€60-300)
80-89	11.2 (637)	€378 (€500)	€204 (€120-300)
90+	1.1 (64)	€246 (€335)	€147 (€90-300)
Sex			
Female	55.6 (3,153)	€310 (€459)	€144 (€0-300)
Male	44.4 (2,515)	€329 (€489)	€144 (€0-360)
Education			
Primary/none	23.6 (1,332)	€241 (€343)	€150 (€60-300)
Secondary	39.6 (2,240)	€306 (€469)	€120 (€0-300)
Third/higher	36.9 (2,096)	€381 (€535)	€156 (€0-480)
Area of residence			
Urban	50.7 (2,873)	€366 (€518)	€168 (€0-360)
Not Urban*	49.3 (2,795)	€270 (€415)	€120 (€0-300)
Marital Status			
Partnered	69.0 (3,911)	€341 (€504)	€144 (€0-360)
Not Partnered	31.0 (1,757)	€269 (€389)	€150 (€30-300)
Private Health Insurance			
Yes	60.4 (3,425)	€401 (€540)	€180 (€0-480)
No	39.6 (2,242)	€193 (€304)	€120 (€24-240)
Long Term Illness (LTI) Scheme			
Yes	7.1 (404)	€307 (€489)	€120 (€12-300)
No	92.9 (5,264)	€319 (€471)	€144 (€0-312)
GMS & GP Entitlements			
GMS Scheme	46.5 (2,632)	€150 (€184)	€120 (€60-240)
GP Visit Card	10.7 (604)	€722 (€652)	€480 (€180-1200)
Neither	42.8 (2,425)	€401 (€549)	€168 (€0-600)
Number of Prescription Medicines (quintiles)**			
0 regular medicines	25.2 (1,429)	€36 (€150)	€0 (€0-0)
1 regular medicine	17.0 (965)	€235 (€362)	€120 (€30-240)
2-3 regular medicines	27.2 (1,539)	€389 (€457)	€240 (€90-480)
4-5 regular medicines	16.7 (948)	€514 (€554)	€240 (€144-720)
6+ regular medicines	13.9 (786)	€562 (€601)	€300 (€204-720)
Number of Chronic Conditions			
0 chronic conditions	17.1 (967)	€111 (€300)	€0 (€0-72)
1 chronic condition	24.9 (1,411)	€251 (€410)	€120 (€0-300)
2 chronic conditions	23.4 (1,327)	€374 (€489)	€180 (€60-432)
3+ chronic conditions	34.6 (1,963)	€432 (€528)	€240 (€120-456)
Complex Multimorbidity			
Yes	2.0 (114)	€360 (€433)	€240 (€120-300)
No	98.0 (5,554)	€318 (€473)	€144 (€0-312)

*Not urban included those who described themselves as rural (n=2,648) and who had missing data (n=147) for this variable.

** Excluded medications not covered by state drug schemes as these are primarily over-the-counter medicines and supplements. Also excluded medications always indicated for a condition covered by the LTI scheme.

Note: SD=Standard Deviation. IQR=Interquartile Range. GMS=General Medical Services. GP= General Practitioner.

Figure 1 shows median out-of-pocket prescription medicine expenditure across three healthcare entitlement categories: GMS scheme, GP Visit Card and neither.




Figure 1. Median (interquartile ranges) out-of-pocket prescription medicine expenditure across healthcare entitlement categories

The median financial burden (percentage of equivalised household income spent on prescription medicines) was 1.3% (IQR=0.0%-3.5%). Mean medicine spend as a percentage of total OOP healthcare spend was 68.4% (SD=37.8%). Descriptive statistics for financial burden and medicine spend as a percentage of total OOP healthcare spend, broken down by demographic variables, are in Appendix A, eTable 3.

3.1 Modelling out-of-pocket prescription medicine expenditure

The analysis showed a statistically significant negative association between being neither GMS eligible nor having a GP visit-card and likelihood of any out-of-pocket prescription medicine expenditure (OR: 0.63, 95%CI: 0.47-0.83), when compared to those with GMS entitlements (Table 3, model a). Compared to GMS eligibility, there was no association between having a GP visit card and the likelihood of any out-of-pocket prescription medicine expenditure (OR: 0.83, 95%CI: 0.56-1.23). There was a statistically significant negative association seen between being eligible for the LTI scheme and reporting any out-of-pocket prescription medicines expenditure (OR: 0.64, 95%CI: 0.44-0.94). Additionally, a statistically significant positive association was found between number of chronic conditions and

likelihood of any out-of-pocket prescription medicine expenditure (OR: 1.47, 95%CI: 1.31-1.64).

Among those with expenditure, the analysis found a statistically significant positive association between being neither GMS eligible nor having a GP visit-card and level of out-of-pocket prescription medicine expenditure (Rate ratio: 4.74, 95%CI: 4.37-5.15), when compared to those who are GMS eligible (Table 3, model b). A statistically significant positive association was also found between having a GP visit card and level of out-of-pocket prescription medicine expenditure (Rate ratio: 4.70, 95%CI: 4.25-4.37), when compared to those who are GMS eligible. The estimated mean expenditure for those who were GMS eligible was €124 (95%CI: €116-€131). For those with a GP visit-card it was €567 (95%CI: €507-€628) and for those who were neither GMS eligible nor had a GP visit-card it was €547 (95%CI: €508-€586).

No statistically significant association was found between eligibility for the LTI scheme and level of out-of-pocket prescription medicines expenditure (Rate ratio: 0.98, 95%CI: 0.87-1.09). The analysis found a statistically significant positive association between number of chronic conditions and level of out-of-pocket prescription medicine expenditure (Rate ratio: 1.08, 95%CI: 1.05-1.11). The results of the multivariable logit regression and multivariable generalised linear model, with number of chronic conditions included as a categorical variable for sensitivity analysis, were similar to the main analysis (see Appendix A, eTable 2).

Table 3. Logit and generalised linear models assessing associations with out-of-pocket (OOP) prescription medicine expenditure

	a) Any OOP expenditure		b) Value of OOP expenditure ^a	
	Odds ratio (95%CI)	p value	Rate ratio (95%CI)	p value
Healthcare entitlements (Ref: GMS scheme)				
GP visit card-holder	0.83 (0.56-1.23)	0.353	4.70 (4.25-5.19)	<0.001
Neither GMS scheme nor GP visit card	0.63 (0.47-0.83)	0.001	4.74 (4.37-5.15)	<0.001
LTI scheme^b	0.64 (0.44-0.94)	0.021	0.98 (0.87-1.09)	0.693
Private Health Insurance^b	1.11 (0.86-1.42)	0.436	1.07 (1.00-1.15)	0.056
Age (years)	1.00 (0.99-1.02)	0.862	1.01 (1.00-1.01)	0.009
Female sex^b	0.75 (0.61-0.93)	0.008	0.91 (0.86-0.97)	0.004
Education (Ref: primary/none)				
Secondary	0.74 (0.55-1.00)	0.049	1.01 (0.93-1.09)	0.874
Third/higher	0.80 (0.58-1.10)	0.177	1.04 (0.96-1.13)	0.360
Number of conditions	1.47 (1.31-1.64)	<0.001	1.08 (1.05-1.11)	<0.001
Complex multimorbidity^b	0.76 (0.52-1.10)	0.148	0.98 (0.90-1.08)	0.733
Number of Prescription Medicines (Ref: 2-3 medicines)				
0 medicines	0.01 (0.01-0.01)	<0.001	0.94 (0.81-1.08)	0.371
1 medicine	0.36 (0.26-0.49)	<0.001	0.65 (0.60-0.71)	<0.001
4-5 medicines	1.18 (0.75-1.85)	0.468	1.44 (1.33-1.56)	<0.001
≥6 medicines	0.73 (0.46-1.14)	0.166	1.89 (1.73-2.06)	<0.001
Urban^b	1.02 (0.83-1.24)	0.876	1.09 (1.03-1.16)	0.002
Partnered^b	1.06 (0.84-1.33)	0.639	1.03 (0.96-1.10)	0.382
Intercept	22.08 (6.35-76.85)	<0.001	81.27 (58.48-112.95)	<0.001

^aModel b includes only those with any out-of-pocket prescription medicine expenditure

Note: The variables are mutually adjusted.

^bReference groups where not indicated are no LTI scheme eligibility, no private health insurance, male sex, no complex multimorbidity, not urban, and not partnered.

Abbreviations: CI, confidence interval; GMS, General Medical Services; GP, general practitioner; LTI, Long Term Illness

3.2 Cost-related non-adherence

Overall, 1.7% (n=89) of the sample reported cost-related non-adherence in the previous 12 months. Those experiencing cost-related non-adherence had higher median expenditure on medicines (€240, IQR: €120- €540) than those not reporting cost-related non-adherence (€150, IQR: €30-€360). There were similar levels of cost related non-adherence for those with GMS entitlements (1.7%, n=42) when compared to those with a GP visit card (1.7%, n=10) and those with neither entitlement (1.6%, n=36) (full cost-related non-adherence details in Table 4).

Table 4. Out-of-pocket (OOP) medicine expenditure and cost-related non-adherence (CRNA)

	Total % (N)	Mean OOP Medicine Expenditure (SD)	Median OOP Medicine Expenditure (IQR)
Proportion reporting any OOP prescription medicine expenditure (N)	73.4% (4,158)	€434 (504)	€240 (€120-€480)
Cost-related non-adherence			
Reporting CRNA in previous 12 months	1.7% (89)	€393 (€464)	€240 (€120-540)
Not reporting CRNA in previous 12 months	98.3% (5,252)	€336 (€480)	€150 (€30-360)
Entitlements and CRNA			
Reporting CRNA with GMS entitlements	1.7% (42)	€201.14 (€192)	€180 (€120-240)
Reporting CRNA with GP visit card entitlements	1.7% (10)	€662.4 (€634)	€480 (€144-960)
Reporting CRNA with neither entitlement	1.6% (36)	€553.67 (€546)	€450 (€48-780)
No. Chronic Conditions and CRNA			
Reporting CRNA with 0 conditions	0.9% (7)	€27.43 (€73)	€0 (€0-0)
Reporting CRNA with 1 condition	1.3% (17)	€329.65 (€336)	€240 (€60-540)
Reporting CRNA with 2 conditions	1.6% (21)	€367.14 (€539)	€240 (€132-360)
Reporting CRNA with 3+ conditions	2.3% (44)	€488.59 (€479)	€300 (€144-720)
Complex multimorbidity and CRNA			
Reporting CRNA with complex multimorbidity	2.7% (3)	€400 (€400)	€300 (€60-840)
Reporting CRNA not with complex multimorbidity	1.6% (86)	€393 (€468)	€240 (€120-540)

In the exploratory univariate logit models (Appendix A, eTable 5), statistically significant associations were identified between cost-related non-adherence and number of chronic conditions (OR: 1.21, 95%CI: 1.07-1.36), complex multimorbidity (OR: 1.96, 95%CI: 1.29-2.98) and being on 4-5 medications (compared to 3 medications) (OR: 1.78, 95%CI: 1.02-3.12). However, these results should be interpreted with caution because in the multivariable model, no statistically significant associations were identified (Table 5). Sensitivity analysis, for the multivariable model, with number of chronic conditions included as a categorical variable (Appendix A, eTable 4) yielded similar results.

Table 5. Model assessing associations with cost-related non-adherence (CRNA)

	Reporting CRNA	
	Odds ratio (95%CI)	p value
Any out-of-pocket prescription medicine expenditure	0.82 (0.35-1.91)	0.644
Out-of-pocket prescription medicine expenditure (per €100)	1.00 (0.94-1.06)	0.869
Any out-of-pocket healthcare (excl. prescription medicines) expenditure	1.31 (0.71-2.43)	0.383
Out-of-pocket healthcare (excl. prescription medicines) expenditure (per €100)	1.01 (0.98-1.04)	0.664
Healthcare entitlements (Ref: GMS scheme)		
GP visit card	1.40 (0.59-3.31)	0.446
Neither GMS scheme nor GP visit card	1.32 (0.62-2.82)	0.472
LTI scheme^a	1.15 (0.54-2.47)	0.711
Private Health Insurance^a	0.61 (0.35-1.04)	0.072
Age (Years)	0.98 (0.95-1.01)	0.286
Female sex^a	1.02 (0.65-1.60)	0.919
Education (Ref: Primary/none)		
Secondary	1.41 (0.79-2.54)	0.247
Third/higher	1.14 (0.59-2.20)	0.704
Number of conditions (per condition)	1.06 (0.86-1.31)	0.557
Complex multimorbidity^a	1.51 (0.78-2.93)	0.222
Number of Prescription Medicines (Ref: 2-3 medicines)		
0 medications	0.51 (0.19-1.39)	0.188
1 medication	1.03 (0.52-2.02)	0.937
4-5 medications	1.70 (0.95-3.05)	0.075
≥6 medications	0.92 (0.44-1.94)	0.824
Urban^a	1.15 (0.75-1.78)	0.513
Partnered^a	0.65 (0.41-1.04)	0.071
Intercept	0.04 (0.00-0.58)	0.018

Note: The variables are mutually adjusted.

^aReference groups where not indicated are no LTI scheme eligibility, no private health insurance, male sex, no complex multimorbidity, not urban, and not partnered.

Abbreviations: CI, confidence interval; GMS, General Medical Services; GP, general practitioner; LTI, Long Term Illness

4. Discussion

4.1 Summary

Those with entitlements to heavily publicly-subsidised prescription medicines had much lower out-of-pocket prescription medicine expenditure than those without those entitlements, clearly showing the strong protective financial effects of the GMS scheme in Ireland in 2016. The estimated mean expenditure for those who were GMS eligible was €124, compared to €567 for those with a GP visit-card and €547 for those with neither entitlement. Adjusting for other factors, this corresponded to more than 4.5 times higher out-of-pocket expenditure on prescription medicines for those without GMS eligibility. Given that GMS entitlements are more common among low-income groups, the strong protective financial effects are likely to be particularly beneficial.⁴³ No association was seen between LTI scheme entitlement and out-of-pocket prescription medicine expenditure. However, if the LTI scheme did not exist in Ireland, then expenditure in this group would likely be far higher because of the high costs of some medicines covered by the scheme e.g. diabetes medicines.⁴⁴ Therefore, the LTI scheme may be acting as an equaliser for those with conditions covered by the scheme.

The number of chronic conditions an individual has was found to be associated with increased out-of-pocket prescription medicine expenditure. People with zero diagnosed chronic conditions, on average, spent €111 annually on prescription medicines, however this is likely skewed by some with high spending as notably, more than 50% of people with zero diagnosed chronic conditions reported spending nothing out-of-pocket on prescription medicines. For people with two conditions, average annual expenditure was €374, and €432 for those with three or more. The finding of increased prescription medicine expenditure for those with multimorbidity is consistent with studies from a range of contexts.^{16,45}

When compared to Denmark, expenditure in for people with multimorbidity is lower than Ireland. An analysis of Danish expenditure in 2020 found that adults with two chronic conditions spent €187 and those with no conditions spent €44.⁴⁵ Data from Korea (adjusted to 2015 values using European Central Bank figures) also showed lower expenditure; average annual expenditure for those aged ≥ 20 years with three or more chronic conditions was €234.¹⁶ Conversely, when compared to data from Canada and the US (adjusted to 2015 values using European Central Bank figures),¹⁶ we find higher out-of-pocket prescription medicine expenditure than for those with multimorbidity in Ireland. In Canada average annual expenditure for those with multimorbidity was €562 among people < 65 years and €762 among those ≥ 65 years.¹⁶ In the US, average annual expenditure for adults aged < 65 years with two chronic conditions was €660, and €882 for those with three conditions.¹⁶

In relation to cost-related non-adherence, only 1.7% of participants had not filled a prescription in the previous 12 months because of cost. This potentially shows the positive effects of the financial protection measures like the GMS scheme. However, it may also be

that non-adherence is underestimated. A 2021/2022 analysis of cost-related medication non-adherence amongst people in Ireland aged ≥ 40 years with one or more chronic condition found that 16% of participants reported not buying a medication (either prescription or non-prescription) in the previous 12 months because of cost.⁴⁶ This is particularly striking given that payment caps had been significantly lowered by 2021/2022, though the difference might, in large part, be accounted for by the inclusion of non-prescription medicines in the 2021/2022 data. When compared to a 2014 analysis of cost-related non-adherence to prescription medications in those aged ≥ 55 years in 11 high-income countries,²² our estimate from the present study would have ranked second lowest among countries. France was the lowest; 1.6% of participants reported cost-related non-adherence to prescription medications in the previous 12 months.²² Whereas 3.1% of UK participants reported cost-related non-adherence despite having much lower prescription charges.²² In the multivariable logit regression no statistically significant associations were found between any included variables and cost-related non-adherence. However, in the univariable analysis, number of chronic conditions, complex multimorbidity and being on 4-5 medications (compared to 3 medications) were positively associated with cost-related non-adherence.

4.2 Implications and further research

One of the primary mechanisms to reduce out-of-pocket prescription medicine expenditure is provision of healthcare entitlements. Given the significant protective effects of the GMS scheme, ensuring full uptake amongst those eligible would be beneficial, as a 2021 study found that 31% of those with an entitlement to the GMS scheme did not have a GMS card.⁴⁷ In relation to improving entitlements, since 2016, DPS and GMS payment caps have been progressively lowered.^{48,49} Consideration is being given to further changes,^{50,51} such as introducing a lower DPS cap for single-headed households or lowering the fee per item for those with GMS entitlements.¹³ The Irish government have explicitly stated that they do not plan to extend the LTI scheme to other conditions.⁵² In relation to welfare entitlement thresholds, organisations such as the Irish Human Rights and Equality Commission have suggested that these thresholds should increase in line with inflation.⁵³ However, there has been limited expansion of entitlements to the GMS scheme,⁵⁴ which provides maximal protection. Instead, GP visit cards entitlements have been extended,⁵⁵ however this group have no additional protection from out-of-pocket prescription medicine expenditure. There may be barriers to increasing healthcare entitlements as, even without any changes to entitlements, the healthcare budget is already expected to take up a greater proportion of the overall state budget due to various factors including the ageing population.⁵⁶ The healthcare budget may also face constraints due to higher public spending on pharmaceuticals than the EU average.³⁷

There are other initiatives that can reduce out-of-pocket prescription medicine expenditure. Prescription medicine prices are higher in Ireland than many other countries.⁵⁷ Various mechanisms could reduce costs for the patient, including increased generic medicine use promoted by reference pricing and encouraging or mandating prescribing by International Nonproprietary Name.^{58,59} Also, fixed mark-ups⁶⁰ or mandated price transparency (to increase competition)⁶¹ on prescription medicines in community pharmacies could reduce costs. However, supply side interventions may have a larger impact on prescription medicine prices.⁶² Examples of this might include shorter monopolies on patented drugs, or limiting the ability of manufacturers to extend patents.⁶² Deprescribing interventions should also be considered, where a healthcare professional evaluates a patient's regular medicines for any that are unnecessary or inappropriate and can therefore be reduced or stopped.⁶³ This can positively affect health outcomes, and reduce out-of-pocket medicine expenditure.⁶³ Cost-of-care conversations (a healthcare professional and patient discussing out-of-pocket healthcare costs and entitlements)⁶⁴ could also reduce expenditure for patients⁶⁵ and improve clinical outcomes (though greater adherence).⁶⁶

Given the Sláintecare aim of universal access to care and current proposed changes to several prescription medicines entitlements,^{13,50,53,67} future research modelling the effects of different entitlement changes would provide valuable evidence. Analysing out-of-pocket prescription medicine expenditure for those <50 years would be valuable as younger populations are more likely to experience cost related non-adherence.³¹ The findings of this study that cost-related non-adherence is low may imply that people are making sacrifices in other areas of their life to afford their healthcare,^{68,69} which could be evaluated in future research.

4.3 Strengths and Limitations

A strength of this study is the nationally representative sample captured by TILDA. In terms of limitations, self-report is associated with recall bias. For example, it can lead to under-reporting of chronic conditions,^{70,71} which may partly be the reason for the somewhat high out-of-pocket prescription medicine expenditure found for those with zero chronic conditions. Though this may also be attributable to medicines for acute conditions or for chronic conditions not captured by TILDA (e.g. menopause and dermatological conditions). There is mixed evidence of the accuracy of self-report for medicine use.^{72,73} Though notably, self-report data from TILDA was found to be accurate for services such as the general practitioner and the outpatient department.⁷⁴ Scaling of reported monthly expenditure to estimate annual out-of-pocket prescription medicine expenditure may not have accurately captured annual expenditure, though the shorter recall period likely reduces recall bias.⁷⁵ Another limitation is that cost-related non-adherence may have been underestimated, possibly because of the highly specific phrasing of the question referring to prescriptions from one's GP. A more

comprehensive and dynamic measure of non-adherence or unmet need may be necessary to accurately capture the issues at play.⁷⁶ The significant exploratory univariate findings for cost-related non-adherence may indicate that the multivariable logit regression is underpowered, or that these associations are partly explained by other factors adjusted for. Measuring financial burden as the percentage of equivalised household income spent on prescription medicines could be considered a limitation. A more valid measure would have been the proportion of non-subsistence income (income remaining after expenditure on subsistence) one spends on healthcare.⁷⁷ However, this is not available from TILDA.

4.4 Conclusion

The entitlements system in Ireland offers significant protection against out-of-pocket prescription medicine expenditure for approximately a third of the population with GMS entitlements, which is mostly those on low incomes. Among those who do not have these protections, out-of-pocket prescription medicine expenditure is much higher, with people who have multimorbidity most at risk of high out-of-pocket prescription medicine expenditure. However, cost-related non-adherence appears to be low. A range of measures could be introduced to reduce out-of-pocket prescription medicine expenditure including increased entitlement thresholds, increased generic prescribing and initiatives to increase the uptake of entitlements, especially for those with multimorbidity

References

1. OECD. Pharmaceutical spending. Accessed 23 February, 2023. <https://data.oecd.org/healthres/pharmaceutical-spending.htm>
2. IQVIA Institute for Human Data Science. The Global Use of Medicines 2024: Outlook to 2028. Accessed 19 February, 2024. <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028>
3. Hammel B, Michel MC. Why are new drugs expensive and how can they stay affordable? *Concepts Principles of Pharmacology: 100 Years of the Handbook of Experimental Pharmacology*. 2019:453-466.
4. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. *JAMA*. 2015;314(17):1818-1830.
5. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. *BMJ Open*. Sep 18 2015;5(9):e008656. doi:10.1136/bmjopen-2015-008656
6. Prendergast C, Flood M, Murry LT, Clyne B, Fahey T, Moriarty F. Prescribing differences among older adults with differing health cover and socioeconomic status: a cohort study. *BMC Geriatr*. Nov 17 2023;23(1):755. doi:10.1186/s12877-023-04441-9
7. Lee H, Baek Y-H, Kim JH, et al. Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: a multinational population-based study. *Age and ageing*. 2023;52(2):afad014.
8. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*. 2015;386(9995):743-800.
9. Pefoyo AJK, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of multimorbidity. *BMC public health*. 2015;15(1):415.
10. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. *Eur J Gen Pract*. 2008;14(sup1):28-32.
11. Kingston A, Robinson L, Booth H, Knapp M, Jagger C, project M. Projections of multimorbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. *Age and ageing*. 2018;47(3):374-380.
12. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. *Age ageing*. 2013;42(1):62-69.
13. Committee on the Future of Healthcare. Sláintecare Report. Accessed 08 August, 2022. <https://assets.gov.ie/22609/e68786c13e1b4d7daca89b495c506bb8.pdf>
14. Australian Government. Concession cards. Accessed 22 May, 2024. <https://www.alrc.gov.au/publication/grey-areas-age-barriers-to-work-in-commonwealth-laws-dp-78/5-social-security/concession-cards/>
15. OECD/World Health Organization/Eurostat. Classification of Health Care Financing Schemes (ICHA-HF). *A System of Health Accounts 2011*. OECD Publishing; 2011.
16. Sum G, Hone T, Atun R, et al. Multimorbidity and out-of-pocket expenditure on medicines: a systematic review. *BMJ global health*. 2018;3(1):e000505.
17. Larkin J, Walsh B, Moriarty F, Clyne B, Harrington P, Smith SM. What is the impact of multimorbidity on out-of-pocket healthcare expenditure among community-dwelling older adults in Ireland? A cross-sectional study. *BMJ Open*. Sep 1 2022;12(9):e060502. doi:10.1136/bmjopen-2021-060502
18. McRae I, Yen L, Jeon YH, Herath PM, Essue B. Multimorbidity is associated with higher out-of-pocket spending: a study of older Australians with multiple chronic conditions. *Aust J Prim Health*. 2013;19(2):144-9. doi:10.1071/py12035
19. Johnston B, Thomas S, Burke S. Can people afford to pay for health care? New evidence on financial protection in Ireland. *Eurohealth*. 2020:1-118.
20. Johnston BM, Burke S, Barry S, Normand C, Fhallúin MN, Thomas S. Private health expenditure in Ireland: Assessing the affordability of private financing of health care. *Health Policy*. 2019;123(10):963-969.

21. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. *Journal of general internal medicine*. 2007;22(6):864-871.
22. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. *BMJ Open*. Jan 31 2017;7(1):e014287. doi:10.1136/bmjopen-2016-014287
23. Sinnott SJ, Normand C, Byrne S, Woods N, Whelton H. Copayments for prescription medicines on a public health insurance scheme in Ireland. *Pharmacoepidemiol Drug Saf*. Jun 2016;25(6):695-704. doi:10.1002/pds.3917
24. Mattsson M, Flood M, Wallace E, Boland F, Moriarty F. Eligibility rates and representativeness of the General Medical Services scheme population in Ireland 2016-2021: A methodological report. *HRB Open Res*. 2022;5:67. doi:10.12688/hrbopenres.13622.1
25. Wren M-A, Connolly S. *Challenges in achieving universal healthcare in Ireland*. Economic and Social Research Institute; 2016.
26. Geary LM, Lynch B, Turner B. The Irish healthcare system: an historical and comparative review. *Dublin: The Health Insurance Authority*. 2018;
27. Health Service Executive. High Tech Drug Arrangements. Accessed 21 May, 2024. <https://www.hse.ie/eng/staff/pdrs/circulars/pharmacy/hi%20tech%20drug%20arrangements%20.pdf>
28. Health Service Executive. Information Guide to HSE Primary Care and Hospital Services for Persons who contracted Hepatitis C through the Administration within the State of Contaminated Blood or Blood Products. Accessed 21 May, 2024. <https://assets.hse.ie/media/documents/haa-information-guide.pdf>
29. Health services Executive. Long Term Illness Scheme. Accessed 29 May, 2023. <https://www2.hse.ie/services/schemes-allowances/lti/about/>
30. Laba T-L, Cheng L, Kolhatkar A, Law MR. Cost-related nonadherence to medicines in people with multiple chronic conditions. *Research in Social and Administrative Pharmacy*. 2020;16(3):415-421.
31. Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. *Soc Sci Med*. Feb 2006;62(4):846-57. doi:10.1016/j.socscimed.2005.06.045
32. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Annals of internal medicine*. 2007;147(8):573-577.
33. Irish Social Science Data Archive. The Irish Longitudinal study on Ageing (TILDA) Wave 4, 2016. Accessed 29 May, 2023. <https://www.ucd.ie/issda/data/tilda/wave4/>
34. TILDA. Documentation - The Irish Longitudinal Study on Ageing (TILDA). Accessed 29 May, 2023. <https://tilda.tcd.ie/data/documentation/>
35. Citizens Information. GP Visit Cards. Accessed 14 September, 2021. https://www.citizensinformation.ie/en/health/medical_cards_and_gp_visit_cards/gp_visit_cards.html
36. Laya Healthcare. What is a Money Smart Cash Back scheme? Accessed 29 May, 2023. <https://www.layahealthcare.ie/info/moneysmart/>
37. OECD/European Observatory on Health Systems and Policies. Ireland: Country Health Profile 2021, State of Health in the EU. *OECD Publishing*. 2021;
38. Turner B, Smith S, Thomson S. Uncovering the complex role of private health insurance in Ireland. *Private health insurance: history, politics and performance*. 2020:221-63.
39. Ryan A, Murphy C, Boland F, Galvin R, Smith SM. What Is the Impact of Physical Activity and Physical Function on the Development of Multimorbidity in Older Adults Over Time? A Population-Based Cohort Study. *J Gerontol A Biol Sci Med Sci*. Oct 8 2018;73(11):1538-1544. doi:10.1093/gerona/glx251
40. Harrison C, Britt H, Miller G, Henderson J. Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice. *BMJ Open*. Jul 11 2014;4(7):e004694. doi:10.1136/bmjopen-2013-004694

41. Organisation for Economic Cooperation and Development. What Are Equivalence Scales? Accessed 22 September, 2021. <https://www.oecd.org/economy/growth/OECD-Note-EquivalenceScales.pdf>
42. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. *Health economics*. 2011;20(8):897-916.
43. Maître B, Privalko I, Watson D. Social Transfers and Deprivation in Ireland: A study of cash and non-cash payments tied to housing, childcare, and primary health care services. ESRI Report November 2020. 2020;
44. McEwen LN, Casagrande SS, Kuo S, Herman WH. Why are diabetes medications so expensive and what can be done to control their cost? *Current Diabetes Reports*. 2017;17:1-7.
45. Larkin J, Smith SM, Christensen LD, et al. The Association between Multimorbidity and Out-of-Pocket Expenditures for Prescription Medicines among Adults in Denmark: A Population-Based Register Study. *medRxiv*. 2023:2023.11. 21.23298458.
46. Larkin J, Foley L, Timmons S, et al. How do People with Multimorbidity Prioritise Healthcare when Faced with Financial Constraints? A Choice Experiment. *medRxiv*. 2023:2023.04. 10.23288383.
47. Keane C, Regan M, Walsh B. Failure to take-up public healthcare entitlements: Evidence from the Medical Card system in Ireland. *Soc Sci Med*. Jul 2021;281:114069. doi:10.1016/j.socscimed.2021.114069
48. Citizens Information. Drugs Payment Scheme. Accessed 24 January, 2024. https://www.citizensinformation.ie/en/health/drugs_and_medicines/drugs_payment_scheme.html
49. Citizens Information. Prescription charges for medical card holders. Accessed 24 January, 2024. https://www.citizensinformation.ie/en/health/drugs_and_medicines/prescription_charges_for_medical_card_holders.html
50. Houses of the Oireachtas. Dáil Éireann Debate, Tuesday - 16 May 2023. Accessed 20 February, 2024. <https://www.oireachtas.ie/en/debates/question/2023-05-16/718/>
51. Burke S, Barry S, Siersbaek R, Johnston B, Ní Fhallúin M, Thomas S. Sláintecare – A ten-year plan to achieve universal healthcare in Ireland. *Health Policy*. 2018/12/01/ 2018;122(12):1278-1282. doi:<https://doi.org/10.1016/j.healthpol.2018.05.006>
52. Houses of the Oireachtas. Departmental Schemes Dáil Éireann Debate, Wednesday - 17 January 2024. Accessed 06 March, 2024. <https://www.oireachtas.ie/en/debates/question/2024-01-17/1744/>
53. Irish Human Rights and Equality Commission. Welfare Indexation Crucial in Combatting Income Inequality. Accessed 20 February, 2024. <https://www.ihrec.ie/welfare-indexation-crucial-in-combatting-income-inequality/>
54. Houses of the Oireachtas. Medical Cards. Accessed 29 March, 2024. https://www.oireachtas.ie/en/debates/question/2024-03-20/1330/#pq_1330
55. Department of Health. Government announces details of the commencement of the provision of GP Visit Cards to over 500,000 more people. Accessed 06 March, 2024. <https://www.gov.ie/en/press-release/45e64-press-release-government-announces-details-of-the-commencement-of-the-provision-of-gp-visit-cards-to-over-500000-more-people/>
56. Sheehan A, O'Sullivan R. Ageing and Public Health: An overview of key statistics in Ireland and Northern Ireland (Presentation). *Dublin: Institute of Public Health*. 2020;
57. Medbelle. 2019 Medicine Price Index. Accessed 27 October, 2021. <https://www.medbelle.com/medicine-price-index-usa/>
58. Kaiser U, Mendez SJ, Rønde T, Ullrich H. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. *Journal of health economics*. 2014;36:174-187.
59. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. *Expert Rev Pharmacoecon Outcomes Res*. Feb 2013;13(1):59-72. doi:10.1586/erp.12.83
60. Österreichisches Bundesinstitut für Gesundheitswesen (ÖBIG). Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states. Accessed 06 March, 2024. <https://jasmin.goeg.at/id/eprint/243/1/Surveying%2C%20Assessing%20and%20Analysing%20the%20Pharmaceutical%20Sector%20in%20the%2025%20EU%20Member%20States.pdf>

61. Larkin J, Moriarty F, McGuinness S, et al. Variation of prescription drug prices in community pharmacies: A national cross-sectional study. *Research in Social and Administrative Pharmacy*. 2022/10/01/ 2022;18(10):3736-3743. doi:<https://doi.org/10.1016/j.sapharm.2022.05.007>
62. Tenni B, Moir HV, Townsend B, et al. What is the impact of intellectual property rules on access to medicines? A systematic review. *Globalization and health*. 2022;18(1):40.
63. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. *JAMA Intern Med*. May 2015;175(5):827-34. doi:10.1001/jamainternmed.2015.0324
64. Hunter WG, Hesson A, Davis JK, et al. Patient-physician discussions about costs: definitions and impact on cost conversation incidence estimates. *BMC Health Serv Res*. Mar 31 2016;16:108. doi:10.1186/s12913-016-1353-2
65. Ubel PA, Abernethy AP, Zafar SY. Full disclosure--out-of-pocket costs as side effects. *N Engl J Med*. Oct 17 2013;369(16):1484-6. doi:10.1056/NEJMp1306826
66. Piette JD, Heisler M, Krein S, Kerr EA. The role of patient-physician trust in moderating medication nonadherence due to cost pressures. *Arch Intern Med*. Aug 8-22 2005;165(15):1749-55. doi:10.1001/archinte.165.15.1749
67. Sinn Féin. ALTERNATIVE BUDGET FOR HEALTH 2024. Accessed 21 February, 2024. https://www.sinnfein.ie/files/2023/AlternativeBudget2024_HealthDoc_September2023_Final.pdf
68. Larkin J, Foley L, Smith SM, Harrington P, Clyne B. The experience of financial burden for people with multimorbidity: A systematic review of qualitative research. *Health Expectations*. 2020;
69. Hess M, Wang R, Workentin A, Woods H, Persaud N. Effect of free medicine distribution on ability to make ends meet: post hoc quantitative subgroup analysis and qualitative thematic analysis. *BMJ Open*. Dec 22 2022;12(12):e061726. doi:10.1136/bmjopen-2022-061726
70. Muggah E, Graves E, Bennett C, Manuel DG. Ascertainment of chronic diseases using population health data: a comparison of health administrative data and patient self-report. *BMC Public Health*. Jan 9 2013;13:16. doi:10.1186/1471-2458-13-16
71. Gruneir A, Griffith LE, Fisher K, et al. Measuring multimorbidity series. An overlooked complexity-comparison of self-report vs. administrative data in community-living adults: paper 3. Agreement across data sources and implications for estimating associations with health service use. *Journal of clinical epidemiology*. 2020;124:173-182.
72. Pit SW, Byles JE, Cockburn J. Accuracy of telephone self-report of drug use in older people and agreement with pharmaceutical claims data. *Drugs Aging*. 2008;25(1):71-80. doi:10.2165/00002512-200825010-00008
73. Allin S, Bayoumi AM, Law MR, Laporte A. Comparability of self-reported medication use and pharmacy claims data. *Health Rep*. Jan 2013;24(1):3-9.
74. Wallace E, Moriarty F, McGarrigle C, Smith SM, Kenny RA, Fahey T. Self-report versus electronic medical record recorded healthcare utilisation in older community-dwelling adults: Comparison of two prospective cohort studies. *PLoS One*. 2018;13(10):e0206201. doi:10.1371/journal.pone.0206201
75. Jobe JB, White AA, Kelley CL, Mingay DJ, Sanchez MJ, Loftus EF. Recall strategies and memory for health-care visits. *The Milbank Quarterly*. 1990:171-189.
76. Smith S, Connolly S. Re-thinking unmet need for health care: introducing a dynamic perspective. *Health economics, policy and law*. 2020;15(4):440-457.
77. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. *Lancet*. Jul 12 2003;362(9378):111-7. doi:10.1016/s0140-6736(03)13861-5

